<DOC>
	<DOC>NCT03030183</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.</brief_summary>
	<brief_title>Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Diagnosis of PNH by flow cytometry Inadequate response to eculizumab defined as having received eculizumab for at least 6 months plus a documented LDH level â‰¥ 1.5 x the upper limit of normal (ULN) and/or the presence of a known C5 mutation conferring resistance to eculizumab History of meningococcal disease Current systemic infection or suspicion of active bacterial infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PNH</keyword>
</DOC>